Home › Weight-loss coverage › Does Michigan Medicaid cover Wegovy & Ozempic

Does Michigan Medicaid cover Wegovy, Ozempic & Zepbound? (2026)

✓ Verified against MDHHS Medicaid pharmacy letter

By Hemant Adhikari, founder of WillItCover · Digested from MDHHS Medicaid pharmacy letter L-25-73 · Last verified July 7, 2026

Short answer: only at BMI 40+. As of January 1, 2026, Michigan Medicaid sharply restricted weight-loss GLP-1s (Wegovy, Zepbound, Saxenda). They're now covered only for members with a BMI of 40 or higher, and only as a step to avoid bariatric surgery. It covers GLP-1s for type 2 diabetes with prior authorization, and offers phentermine and Qsymia as preferred anti-obesity alternatives.

What changed on January 1, 2026

Under MDHHS Medicaid pharmacy letter L-25-73, weight-loss GLP-1 coverage narrowed dramatically. To be approved for a weight-loss GLP-1, a member now must:

Requirement	What it means
BMI 40 or higher	Coverage requires morbid obesity (BMI 40+).
Failed other interventions	Documented failure of all other clinically appropriate weight-loss interventions, and trial/failure of the preferred anti-obesity agents (phentermine, Qsymia).
To avert bariatric surgery	The drug must be used as a measure to avoid the need for bariatric surgery.

Digested from MDHHS Medicaid pharmacy letter L-25-73, effective January 1, 2026. Members already on a GLP-1 lose coverage when their current authorization expires unless they meet the new criteria. Last verified July 7, 2026.

What's covered — GLP-1s for type 2 diabetes

Michigan Medicaid covers GLP-1 drugs such as Ozempic, Mounjaro, Trulicity, Rybelsus and Victoza for type 2 diabetes with prior authorization. The prior authorization typically looks for a documented type 2 diabetes diagnosis and, often, a trial of a first-line oral drug such as metformin.

Alternatives and other paths

Phentermine and Qsymia are covered as preferred anti-obesity medications — often the first step now.
Non–weight-loss indications are still covered: Zepbound for obstructive sleep apnea, and Wegovy for established cardiovascular disease or severe liver disease.
If you also have Medicare (dual-eligible), the Medicare GLP-1 Bridge ($50/month, July 2026–Dec 2027) may be an option. See how the Bridge works →

Not sure where you stand? Check in two minutes

Tell us your plan, drug and reason, and see whether you're likely covered — plus exactly what to document or how to appeal.

Check my coverage

Frequently asked questions

Does Michigan Medicaid cover Wegovy for weight loss?

Only in limited cases as of January 1, 2026. Coverage requires a BMI of 40 or higher, documented failure of other weight-loss interventions including the preferred agents phentermine and Qsymia, and use of the drug to avoid bariatric surgery.

I was already on a GLP-1 — will Michigan Medicaid keep covering it?

Not automatically. If you don't meet the new BMI-40 criteria, coverage ends when your current six-month authorization expires. Talk to your prescriber about alternatives or a covered indication.

Does Michigan Medicaid cover Ozempic for diabetes?

Yes. GLP-1s such as Ozempic and Mounjaro remain covered for type 2 diabetes with prior authorization.

What weight-loss drugs does Michigan Medicaid prefer?

Phentermine and Qsymia (phentermine/topiramate) are covered as preferred anti-obesity medications. GLP-1s are reserved for BMI 40+ members using them to avert bariatric surgery.

How we know this: this page is based on MDHHS Medicaid pharmacy letter L-25-73 (effective January 1, 2026), which limits weight-loss GLP-1 coverage to members with a BMI of 40+ using the drug to avert bariatric surgery, and covers phentermine and Qsymia as preferred alternatives. Medicaid drug rules change frequently and managed-care plans vary — we re-verify this page against the source and date it. Last verified July 7, 2026. This is general information, not medical or coverage advice, and not a guarantee — your specific plan controls.